Literature DB >> 27721921

Is MELD score failing patients with liver disease and hepatorenal syndrome?

Lena Sibulesky1, Nicolae Leca1, Christopher Blosser1, Amir A Rahnemai-Azar1, Renuka Bhattacharya1, Jorge Reyes1.   

Abstract

There is a need to reassess the application of MELD and the impact of renal insufficiency with consideration for developing an algorithm with exception points that would lead to timely allocation of livers to patients with hepatorenal syndrome prior to occurrence of permanent renal damage without jeopardizing post-transplant survival.

Entities:  

Keywords:  Cirrhosis; Graft survival; Hepatorenal syndrome; Liver allocation; MELD

Year:  2016        PMID: 27721921      PMCID: PMC5037329          DOI: 10.4254/wjh.v8.i27.1155

Source DB:  PubMed          Journal:  World J Hepatol


Core tip: The decompensation of patients with cirrhosis is associated with the development of hepatorenal syndrome (HRS) and renal insufficiency. There are several consequences of a high serum creatinine level in cirrhotic patients, including increased post - liver transplant mortality and increased risk of non-reversal of renal insufficiency/renal failure. We propose a change to the MELD scoring that would lead to timely liver transplantation in patients with HRS.

TO THE EDITOR

The decompensation of patients with cirrhosis is associated with the development of complications. This physiology can lead to renal hypoperfusion which contributes to the development of hepatorenal syndrome (HRS) and renal insufficiency[1,2]. It is rare to develop HRS with well-compensated liver disease. There are several consequences of a high serum creatinine level in cirrhotic patients. Serum creatinine is one of the most important independent predictors of waitlist and post-liver transplant (LT) mortality. While having the same MELD score, patients with higher serum creatinine level have a significantly higher mortality rate[3]. Analysis of the Scientific Registry of Transplant Recipients database linked with Centers for Medicare and Medicaid Services’ end-stage renal disease (ESRD) data by Sharma et al[4] demonstrated that post-LT ESRD is associated with higher post-LT mortality (HR = 3.32; P < 0.0001). Serum creatinine prior to liver transplantation is one of the most significant predictors of post-liver transplantation ESRD[5]. Wong et al[6] recently demonstrated that the only predictor of type 1 HRS non-reversal was the duration of pre-transplant dialysis with a 6% increased risk of non-reversal with each additional day of dialysis. Prolonged ischemic physiology may lead to structural renal damage and thus, prevent renal recovery. This has led many to consider combined liver-kidney transplantation (CLKT) for patients whose HRS has lasted longer than 6 wk because the outcomes for patients who receive CLKT seem to be better than those of patients who receive a liver transplant alone[7,8]. Since the introduction of MELD score, the number of patients treated with CLKT has increased markedly[9]. Almost 1000 kidneys a year are used in a combined transplantation, thus, diminishing the donor pool for patients on the kidney list. It has also been shown that patients with renal insufficiency have longer hospital and intensive care unit stays and an increased need for dialysis, which likely increases the cost of transplantation. It likely adds to already increased healthcare costs through additional dialysis cases, and increased hospitalization rates secondary to morbidities associated with ESRD[10]. While MELD score is the gold standard for predicting wait list mortality, a notable weakness for liver allocation lies in predicting post transplantation survival, particularly with renal insufficiency[11,12]. In addition to MELD, various scoring systems, including Child Pugh score, the risk, injury, failure, loss, end-stage kidney disease criteria, sequential organ failure assessment (SOFA) score, and the Chronic Liver Failure-SOFA score have been designed to predict outcomes in post liver transplant patients[13]. Without a timely liver transplant for patients with acute kidney injury, the patient mortality is shifting from the waitlist to the post-transplant period[14]. It is time for a conversation within the transplant community to reassess the application of MELD and the impact of renal insufficiency with consideration for developing an algorithm with exception points that would lead to timely allocation of livers to patients with HRS prior to occurrence of permanent renal damage without jeopardizing post-transplant survival.
  13 in total

1.  Diagnosis and management of acute kidney injury in patients with cirrhosis: revised consensus recommendations of the International Club of Ascites.

Authors:  Paolo Angeli; Pere Ginès; Florence Wong; Mauro Bernardi; Thomas D Boyer; Alexander Gerbes; Richard Moreau; Rajiv Jalan; Shiv K Sarin; Salvatore Piano; Kevin Moore; Samuel S Lee; Francois Durand; Francesco Salerno; Paolo Caraceni; W Ray Kim; Vicente Arroyo; Guadalupe Garcia-Tsao
Journal:  J Hepatol       Date:  2015-01-28       Impact factor: 25.083

2.  Outcomes of patients with cirrhosis and hepatorenal syndrome type 1 treated with liver transplantation.

Authors:  Florence Wong; Wesley Leung; Mohammed Al Beshir; Max Marquez; Eberhard L Renner
Journal:  Liver Transpl       Date:  2015-02-10       Impact factor: 5.799

3.  Outcome of patients with renal insufficiency undergoing liver or liver-kidney transplantation.

Authors:  R S Brown; M Lombardero; J R Lake
Journal:  Transplantation       Date:  1996-12-27       Impact factor: 4.939

4.  Effect of pretransplant serum creatinine on the survival benefit of liver transplantation.

Authors:  Pratima Sharma; Douglas E Schaubel; Mary K Guidinger; Robert M Merion
Journal:  Liver Transpl       Date:  2009-12       Impact factor: 5.799

5.  Outcomes after liver transplantation: chronic kidney disease.

Authors:  Ranjeeta Bahirwani; K Rajender Reddy
Journal:  Liver Transpl       Date:  2009-11       Impact factor: 5.799

6.  Declining outcomes in simultaneous liver-kidney transplantation in the MELD era: ineffective usage of renal allografts.

Authors:  Jayme E Locke; Daniel S Warren; Andrew L Singer; Dorry L Segev; Christopher E Simpkins; Warren R Maley; Robert A Montgomery; Gabriel Danovitch; Andrew M Cameron
Journal:  Transplantation       Date:  2008-04-15       Impact factor: 4.939

Review 7.  Acute kidney injury in cirrhosis.

Authors:  Guadalupe Garcia-Tsao; Chirag R Parikh; Antonella Viola
Journal:  Hepatology       Date:  2008-12       Impact factor: 17.425

8.  Model of end stage liver disease (MELD) score greater than 23 predicts length of stay in the ICU but not mortality in liver transplant recipients.

Authors:  Christian E Oberkofler; Philipp Dutkowski; Reto Stocker; Reto A Schuepbach; John F Stover; Pierre-Alain Clavien; Markus Béchir
Journal:  Crit Care       Date:  2010-06-15       Impact factor: 9.097

Review 9.  Predicting survival after liver transplantation based on pre-transplant MELD score: a systematic review of the literature.

Authors:  Kristin B Klein; Taenia D Stafinski; Devidas Menon
Journal:  PLoS One       Date:  2013-12-12       Impact factor: 3.240

10.  Scoring systems for predicting mortality after liver transplantation.

Authors:  Heng-Chih Pan; Chang-Chyi Jenq; Wei-Chen Lee; Ming-Hung Tsai; Pei-Chun Fan; Chih-Hsiang Chang; Ming-Yang Chang; Ya-Chung Tian; Cheng-Chieh Hung; Ji-Tseng Fang; Chih-Wei Yang; Yung-Chang Chen
Journal:  PLoS One       Date:  2014-09-12       Impact factor: 3.240

View more
  4 in total

1.  Urinary NGAL as a Diagnostic and Prognostic Marker for Acute Kidney Injury in Cirrhosis: A Prospective Study.

Authors:  Andrew S Allegretti; Xavier Vela Parada; Paul Endres; Sophia Zhao; Scott Krinsky; Shelsea A St Hillien; Sahir Kalim; Sagar U Nigwekar; James G Flood; Andrea Nixon; Douglas A Simonetto; Luis A Juncos; Nithin Karakala; Hani M Wadei; Kevin R Regner; Justin M Belcher; Mitra K Nadim; Guadalupe Garcia-Tsao; Juan Carlos Q Velez; Samir M Parikh; Raymond T Chung
Journal:  Clin Transl Gastroenterol       Date:  2021-05-11       Impact factor: 4.396

2.  Hepatorenal syndrome: Update on diagnosis and therapy.

Authors:  Juan G Acevedo; Matthew E Cramp
Journal:  World J Hepatol       Date:  2017-02-28

3.  Development and validation of a prognostic model for patients with hepatorenal syndrome: A retrospective cohort study.

Authors:  Xin-Yu Sheng; Fei-Yan Lin; Jian Wu; Hong-Cui Cao
Journal:  World J Gastroenterol       Date:  2021-05-28       Impact factor: 5.742

4.  Hepatorenal syndrome: role of the transjugular intrahepatic stent shunt in real life practice.

Authors:  Gianni Testino
Journal:  Clujul Med       Date:  2017-10-20
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.